Pomerantz LLP is investigating claims on behalf of investors of DXC Technology Company concerning whether DXC and certain officers and directors engaged in securities fraud or other unlawful business practices. The investigation follows DXC's May 7, 2026, fourth-quarter and full-year fiscal 2026 results, which showed total revenue of approximately $3.13 billion, a 1.2% year-over-year decline and a 6.6% decline on an organic basis, along with fourth-quarter bookings of approximately $3.3 billion, down 13.5% year over year. Management disclosed that the company missed its organic revenue guidance by approximately $75 million, or two percentage points, citing both pipeline and execution issues, and issued fiscal year 2027 guidance projecting continued organic revenue decline of approximately 3% to 5% year over year. On this news, DXC's stock price fell $2.58 per share, or 21.48%, to close at $9.43 per share on May 8, 2026.
DXC Technology CoDXC missed organic revenue guidance by $75M, reported declining revenue and bookings, and issued weak FY2027 guidance, causing a 21.48% stock drop.